AOBiome
Cambridge
About AOBiome
AOBiome is a life sciences company that focuses on transforming human health by developing microbiome-based therapies for inflammatory conditions. The company's portfolio includes multiple clinical-stage programs; a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. Its product candidates harness a single strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria (AOB), a human commensal, enabling healthcare practitioners to produce well-understood and well-characterized biochemical compound that are critical to human health. AOBiome was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $38.7M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2017)
- Website: aobiome.com
- Phone: (617) 401-3190
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/aobiome-111860 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.